Clindamycin Phosphate With Benzoyl Peroxide, Gel
Not recommended DermatologyRestricted
Treatment of moderate acne vulgaris with inflammatory lesions in patients with an inadequate response to a minimum of two over-the-counter products.
1
Submissions
2009–09
On the record
$45k–75k
ICER range
1 sourced ICER · 2009
ICER stated
Cost basis
Decision on record
- Meeting Mar 2009 Not recommended Acne treatment
Cost-effectiveness
Base case submitted as less than $15,000 per QALY, but PBAC recalculation with corrected utility values yields ICER in range $45,000–$75,000 per QALY. Further sensitivity analyses would produce higher values.
ICER uncertainICER / price too highEconomic model disputed
Decision context
Populationpatients with moderate acne vulgaris with inflammatory lesions who have an inadequate response to at least two over-the-counter medications
Why it was knocked back
- Unacceptably high and uncertain cost effectiveness; considerable uncertainty in QALY modelling approach (psoriasis-based mapping algorithm, Korean population QOL generalisability, utility assumptions); uncertainty regarding clinical place and potential for long-term use; unclear definition of mild to moderate acne; concern regarding development of antibiotic resistance and increase in community acquired MRSA resistance
Submission history
| Decided | Outcome | Comparator | ICER | Evidence |
|---|---|---|---|---|
| Mar 2009 | Not recommended | no treatment (placebo) | $45k–75k | RCT · QOL, global improvement in acne vulgaris of the face |
Similar precedents
Regulatory · TGA
Label narrower than PBS population — PBAC restricts to moderate acne with inflammatory lesions and prior inadequate response to ≥2 OTC products; TGA label includes all comedo, papular, and pustular acne.